Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 11, 2007

Maas Biolab Awarded $2.1M to Enable Studies on Intrathecal Delivery of ALS Drug

  • Maas Biolab received an SBIR grant of $2.1 million to advance research on its drug candidate for amyotrophic lateral sclerosis (ALS). The National Institute of Neurological Disorders and Stroke grant extends over three years.

    The compound, known as Mitogard®, is a formulation of the direct mitochondrial neuroprotectant cyclosporine. It is the only cyclosporine compound designed for cerebrospinal fluid administration, according to Maas Biolab.

    The company believes that intrathecal delivery of Mitogard will overcome challenges faced by systemic cyclosporine, which does not easily reach the brain and spinal cord. Dose-escalation toxicology and pharmacokinetics safety studies will be performed by Northern Biomedical Research to enable IND approval for ALS clinical trials.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »